Exhibit 99.1 INVENTIVA S.A. A joint-stock company (société anonyme) with a share capital of 386,593.61euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2021 Table of contents | 1. | Interim Financial Report | 2 | | --- | --- | --- | | 1.1. | General overview of activities | 2 | | 1.2. | Significant events in first-half 2021 | 2 | | 1.3. | Recent events and prospects | 5 | | 1.4. | Risk facto ...

inventiva | --- | --- | --- | --- | --- | --- | --- | --- | |-----------|------------------------|-------|-------|------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | Developing innovative therapies in | | | | | | NASH and MPS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Corporate Presentation | | | | | | | | June 2021 | | | | | | | | | | | | | | | | | DISCLAIMER This presentation contains forward-looking sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F | (Mark One) | | | --- | --- | | ☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | | ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended December 31, 2020 | | | OR | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | OR | | ☐ | SHELL COMPANY REPORT PU ...

Inventiva S.A. (OTCPK:IVEVF) Q4 2020 Earnings Conference Call March 5, 2021 8:00 AM ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer and Co-Founder Pierre Broqua - Chief Scientific Officer and Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial Officer Conference Call Participants Etzer Darout - Guggenheim Lucy Codrington - Jefferies Lenny Van Steenhuyse - KBC Jean-Jacques Le Fur - Bryan, Garnier Zegbeh Jallah - ROTH Capital Michael Morabito - Chardan ...

inventiva | --- | --- | --- | --- | --- | --- | --- | --- | |------------|------------------------|-------|-------|------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | Developing innovative therapies in | | | | | | NASH and MPS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Corporate Presentation | | | | | | | | March 2021 | | | | | | | | | | | | | | | | | | | | | | | | | | DISCLAIMER This presentation contains ...